Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes

Lorraine E Levitt Katz,Fida Bacha,Samuel S. Gidding,Ruth S. Weinstock,Laure El Ghormli,Ingrid Libman,Kristen J. Nadeau,Kristin Porter,Santica M. Marcovina,S. McKay,M. Haymond,B. Anderson,C. Bush,S. Gunn,H. Holden,S.M. Jones,G. Jeha,S. McGirk,S. Thamotharan,L. Cuttler,E. Abrams,T. Casey,W. Dahms,C. Ievers-Landis,B. Kamiński,M. Koontz,S. MacLeish,P. McGuigan,S. Narasimhan,M. Geffner,V. Barraza,N. Chang,B. Conrad,D. Dreimane,S. Estrada,L. Fisher,E. Fleury-Milfort,S. Hernández,B. Hollen,F. Kaufman,E. Law,V. Mansilla,D. Miller,C. Muñoz,R. Ortiz,A. Ward,K. Wexler,Y.K. Xu,P. Yasuda,R. Berkowitz,S. Boyd,B. Johnson,J. Kaplan,C. Keating,C. Lassiter,T. Lipman,G. McGinley,H. McKnight,B. Schwartzman,S. Willi,S. Arslanian,S. Foster,B. Galvin,T. Hannon,A. M. Kriska,M. Marcus,T. Songer,E. Venditti,R. Goland,D. Gallagher,P. Kringas,N. Leibel,D. Ng,M. Ovalles,D. Seidman,L. Laffel,A. Goebel-Fabbri,M. Hall,L. Higgins,J. Keady,M. Malloy,K. Milaszewski,L. Rasbach,D.M. Nathan,A. Angelescu,L. Bissett,C. Ciccarelli,L. Delahanty,V. Goldman,O. Hardy,M. Larkin,L. Levitsky,R. McEachern,D. Norman,D. Nwosu,S. Park-Bennett,D. Richards,N. Sherry,B. Steiner,S. Tollefsen,S. Carnes,D. Dempsher,D. Flomo,T. Whelan,B. Wolff,D. Bowerman,S. Bristol,J. Bulger,J. Hartsig,R. Izquierdo,J. Kearns,R. Saletsky,P. Trief,P. Zeitler,N. Abramson,A. Bradhurst,N. Celona-Jacobs,J. Higgins,M. Kelsey,G. Klingensmith,T. Witten,K. Copeland,E. Boss,R. Brown,J. Chadwick,L. Chalmers,S. Chernausek,A. Hebensperger,C. Macha,R. Newgent,A. Nordyke,D. Olson,T. Poulsen,L. Pratt,J. Preske,J. Schanuel,S. Sternlof,J. Lynch,N. Amodei,R. Barajas,C. Cody,D. Hale,C. Ibarra,E. Morales,S. Rivera,G. Rupert,A. Wauters,N. White,A. Arbeláez,J. Jones,T. Jones,M. Sadler,M. Tanner,A. Timpson,R. Welch,S. Caprio,M. Grey,C. Guandalini,S. Lavietes,P. Rose,A. Syme,W. Tamborlane,K. Hirst,S. Edelstein,P. Feit,N. Grover,C. Long,L. Pyle,B. Linder,J. Harting,J. Shepherd,B. Fan,L. Marquez,M. Sherman,J. Wang,M. Nichols,E. Mayer-Davis,Y. Liu,J. Lima,J. Puccella,E. Ricketts,R. Danis,Amitha Domalpally,A. Goulding,S. Neill,P. Vargo,D. Wilfley,D. Aldrich-Rasche,K. Franklin,C. Massmann,D. O'brien,J. Patterson,T. Tibbs,D. Van Buren,M. Palmert,R. Ratner,J. Silverstein,J. Hernández,D. Dremaine;Lorraine E Levitt Katz;Fida Bacha;Samuel S. Gidding;Ruth S. Weinstock;Laure El Ghormli;Ingrid Libman;Kristen J. Nadeau;Kristin Porter;Santica M. Marcovina;S. McKay;M. Haymond;B. Anderson;C. Bush;S. Gunn;H. Holden;S.M. Jones;G. Jeha;S. McGirk;S. Thamotharan;L. Cuttler;E. Abrams;T. Casey;W. Dahms;C. Ievers-Landis;B. Kamiński;M. Koontz;S. MacLeish;P. McGuigan;S. Narasimhan;M. Geffner;V. Barraza;N. Chang;B. Conrad;D. Dreimane;S. Estrada;L. Fisher;E. Fleury-Milfort;S. Hernández;B. Hollen;F. Kaufman;E. Law;V. Mansilla;D. Miller;C. Muñoz;R. Ortiz;A. Ward;K. Wexler;Y.K. Xu;P. Yasuda;R. Berkowitz;S. Boyd;B. Johnson;J. Kaplan;C. Keating;C. Lassiter;T. Lipman;G. McGinley;H. McKnight;B. Schwartzman;S. Willi;S. Arslanian;S. Foster;B. Galvin;T. Hannon;A. M. Kriska;M. Marcus;T. Songer;E. Venditti;R. Goland;D. Gallagher;P. Kringas;N. Leibel;D. Ng;M. Ovalles;D. Seidman;L. Laffel;A. Goebel-Fabbri;M. Hall;L. Higgins;J. Keady;M. Malloy;K. Milaszewski;L. Rasbach;D.M. Nathan;A. Angelescu;L. Bissett;C. Ciccarelli;L. Delahanty;V. Goldman;O. Hardy;M. Larkin;L. Levitsky;R. McEachern;D. Norman;D. Nwosu;S. Park-Bennett;D. Richards;N. Sherry;B. Steiner;S. Tollefsen;S. Carnes;D. Dempsher;D. Flomo;T. Whelan;B. Wolff;D. Bowerman;S. Bristol;J. Bulger;J. Hartsig;R. Izquierdo;J. Kearns;R. Saletsky;P. Trief;P. Zeitler;N. Abramson;A. Bradhurst;N. Celona-Jacobs;J. Higgins;M. Kelsey;G. Klingensmith;T. Witten;K. Copeland;E. Boss;R. Brown;J. Chadwick;L. Chalmers;S. Chernausek;A. Hebensperger;C. Macha;R. Newgent;A. Nordyke;D. Olson;T. Poulsen;L. Pratt;J. Preske;J. Schanuel;S. Sternlof;J. Lynch;N. Amodei;R. Barajas;C. Cody;D. Hale;C. Ibarra;E. Morales;S. Rivera;G. Rupert;A. Wauters;N. White;A. Arbeláez;J. Jones;T. Jones;M. Sadler;M. Tanner;A. Timpson;R. Welch;S. Caprio;M. Grey;C. Guandalini;S. Lavietes;P. Rose;A. Syme;W. Tamborlane;K. Hirst;S. Edelstein;P. Feit;N. Grover;C. Long;L. Pyle;B. Linder;J. Harting;J. Shepherd;B. Fan;L. Marquez;M. Sherman;J. Wang;M. Nichols;E. Mayer-Davis;Y. Liu;J. Lima;J. Puccella;E. Ricketts;R. Danis;Amitha Domalpally;A. Goulding;S. Neill;P. Vargo;D. Wilfley;D. Aldrich-Rasche;K. Franklin;C. Massmann;D. O'brien;J. Patterson;T. Tibbs;D. Van Buren;M. Palmert;R. Ratner;J. Silverstein;J. Hernández;D. Dremaine;
the journal of pediatrics 2018 Vol. 196 pp. 208-216.e2
222
dremaine2018thelipid

Abstract

Data regarding atherogenic dyslipidemia and the inflammation profile in youth with type 2 diabetes is limited and the effect of insulin therapy on these variables has not previously been studied in youth. We determined the impact of insulin therapy on lipid and inflammatory markers in youth with poorly controlled type 2 diabetes. In the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) multicenter trial, 285 participants failed to sustain glycemic control on randomized treatment (primary outcome, glycated hemoglobin A1c [HbA1c] at ≥8% for 6 months); 363 maintained glycemic control (never reached primary outcome). Statins were used for a low-density lipoprotein cholesterol of ≥130 mg/dL. Upon reaching the primary outcome, insulin was started. Changes in lipids and inflammatory markers (slopes over time) were examined. Progression of dyslipidemia was related to glycemic control. In those with the primary outcome, insulin therapy impacted HbA1c modestly, and dampened the increase in total cholesterol, low-density lipoprotein cholesterol, and total apolipoprotein B, although statin use increased from 8.6% to 22% year after the primary outcome. The increase in triglycerides and plasma nonesterified fatty acids stabilized after insulin was started, independent of HbA1c. There was an increase in high-sensitivity C-reactive protein that continued after insulin initiation, related to HbA1c and percent overweight. Worsening dyslipidemia and inflammation over time raise concern regarding premature development of atherosclerosis in youth with type 2 diabetes. Insulin therapy has a limited benefit in the absence of glycemic control. Strategies to achieve better glycemic control are needed. ClinicalTrials.gov: NCT00081328.

Keywords

Adolescent type 2 diabetes mellitus insulin lipids inflammatory markers

Access

DOI:
10.1016/j.jpeds.2017.12.052
URL:
https://sciprofiles.com/publication/view/9639615b6...

Citation

ID: 113899
Ref Key: dremaine2018thelipid
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
113899
Unique Identifier:
10.1016/j.jpeds.2017.12.052
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store